XASX
CTE
Market cap42mUSD
Jun 30, Last price
1.25AUD
Name
Cryosite Ltd
Chart & Performance
P/E
32.38
P/S
4.32
EPS
0.04
Div Yield, %
5.60%
Shrs. gr., 5y
—
Rev. gr., 5y
9.62%
Revenues
14m
+11.93%
Net income
2m
+2.39%
CFO
2m
-24.75%
Dividend
Sep 06, 20240.02 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cryosite Limited, founded in 1999 and headquartered in South Granville, Australia, specializes in providing outsourced logistics and storage solutions to the life sciences industry within Australia. The company operates through two distinct divisions. Its Clinical Trials and Biological Services Logistics segment offers comprehensive support to the clinical research and pharmaceutical sectors, encompassing services such as specialized temperature-controlled and general biological storage, precise labeling, secondary packaging, and end-to-end supply chain management capabilities like scheduled drug distribution, returns processing, material destruction, status oversight, comparator sourcing, and validated import/export and transportation. The second division, Cord Blood and Tissues Storage, focuses on the long-term cryogenic preservation of cord blood and tissue samples. Cryosite's client base spans the research, medical, pharmaceutical, veterinary, and biotechnology industries.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||